PURPOSE: Many cancer patients take antioxidant vitamin supplements with the hope of improving the outcome of conventional therapies and of reducing the adverse effects of these treatments. A randomized trial was conducted to determine whether supplementation with antioxidant vitamins could reduce the occurrence and severity of acute adverse effects of radiation therapy and improve quality of life without compromising treatment efficacy. PATIENTS AND METHODS: We conducted a randomized, double-blind, placebo-controlled trial among 540 head and neck cancer patients treated withradiation therapy. Patients were randomly assigned into two arms. The supplementation with alpha-tocopherol (400 IU/d) and beta-carotene (30 mg/d) or placebos was administered during radiation therapy and for 3 years thereafter. During the course of the trial, supplementation with beta-carotene was discontinued because of ethical concerns. RESULTS: Patients randomly assigned in the supplement arm tended to have less severe acute adverse effects during radiation therapy (odds ratio [OR], 0.72; 95% CI, 0.52 to 1.02). The reduction was statistically significant when the supplementation combined alpha-tocopherol and beta-carotene for adverse effects to the larynx (OR, 0.38; 95% CI, 0.21 to 0.71) and overall at any site (OR, 0.38; 95% CI, 0.20 to 0.74). Quality of life was not improved by the supplementation. The rate of local recurrence of the head and neck tumor tended to be higher in the supplement arm of the trial (hazard ratio, 1.37; 95% CI, 0.93 to 2.02). CONCLUSION: Supplementation with high doses of alpha-tocopherol and beta-carotene during radiation therapy could reduce the severity of treatment adverse effects. However, this trial suggests that use of high doses of antioxidants as adjuvant therapy might compromise radiation treatment efficacy.
RCT Entities:
PURPOSE: Many cancerpatients take antioxidant vitamin supplements with the hope of improving the outcome of conventional therapies and of reducing the adverse effects of these treatments. A randomized trial was conducted to determine whether supplementation with antioxidant vitamins could reduce the occurrence and severity of acute adverse effects of radiation therapy and improve quality of life without compromising treatment efficacy. PATIENTS AND METHODS: We conducted a randomized, double-blind, placebo-controlled trial among 540 head and neck cancerpatients treated with radiation therapy. Patients were randomly assigned into two arms. The supplementation with alpha-tocopherol (400 IU/d) and beta-carotene (30 mg/d) or placebos was administered during radiation therapy and for 3 years thereafter. During the course of the trial, supplementation with beta-carotene was discontinued because of ethical concerns. RESULTS:Patients randomly assigned in the supplement arm tended to have less severe acute adverse effects during radiation therapy (odds ratio [OR], 0.72; 95% CI, 0.52 to 1.02). The reduction was statistically significant when the supplementation combined alpha-tocopherol and beta-carotene for adverse effects to the larynx (OR, 0.38; 95% CI, 0.21 to 0.71) and overall at any site (OR, 0.38; 95% CI, 0.20 to 0.74). Quality of life was not improved by the supplementation. The rate of local recurrence of the head and neck tumor tended to be higher in the supplement arm of the trial (hazard ratio, 1.37; 95% CI, 0.93 to 2.02). CONCLUSION: Supplementation with high doses of alpha-tocopherol and beta-carotene during radiation therapy could reduce the severity of treatment adverse effects. However, this trial suggests that use of high doses of antioxidants as adjuvant therapy might compromise radiation treatment efficacy.
Authors: Danielle N Margalit; Julie L Kasperzyk; Neil E Martin; Howard D Sesso; John Michael Gaziano; Jing Ma; Meir J Stampfer; Lorelei A Mucci Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-11 Impact factor: 7.038
Authors: Heather Greenlee; Marilyn L Kwan; Lawrence H Kushi; Jun Song; Adrienne Castillo; Erin Weltzien; Charles P Quesenberry; Bette J Caan Journal: Cancer Date: 2011-09-27 Impact factor: 6.860
Authors: Donald P Braun; Digant Gupta; Timothy C Birdsall; Michele Sumner; Edgar D Staren Journal: J Altern Complement Med Date: 2012-10-04 Impact factor: 2.579
Authors: Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini Journal: J Cancer Res Clin Oncol Date: 2019-01-30 Impact factor: 4.553
Authors: C M L van Herpen; M E Mauer; R Mesia; M Degardin; S Jelic; C Coens; J Betka; J Bernier; E Remenar; J S Stewart; J H Preiss; D van den Weyngaert; A Bottomley; J B Vermorken Journal: Br J Cancer Date: 2010-09-14 Impact factor: 7.640